Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

By F. Hodi, M. Mihm, R. Soiffer, F. Haluska, M. Butler, M. Seiden, T. Davis, Rochele Henry-Spires, Suzanne Macrae, Ann M. Willman and 7 more. Proceedings of the National Academy of Sciences of the United States of America, 2003

1,020 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/e6d5c03fee46baa88d12f01d4b306f857284d43d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. James P. Allison
2. S. Rosenberg
3. J. Wolchok
4. D. Gabrilovich
5. G. Dranoff
6. Jie Yang
7. S. Topalian
8. R. Sherry

In Oncology

1. James P. Allison
2. S. Rosenberg
3. J. Wolchok
4. Jie Yang
5. S. Topalian
6. C. Robert
7. G. Dranoff
8. R. Sherry

Citations in the corpus

• Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018, background): “The anti-CTLA-4 blocking antibody ipilimumab was the first immune checkpoint inhibitor to be tested and approved for the treatment of cancer patients (19, 20).”
• Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (2007, background): “prostate cancer.(12) Many of these patients had received concurrent or prior antitumor vaccines and based on murine models, it was hypothesized that these vaccines may have also contributed to the responses seen.”
• Immunosuppressive strategies that are mediated by tumor cells. (2007, background): “An interesting finding by Dranoff`s group was the demonstration of the efficacy of CTLA-4 blockade in patients who had previously been vaccinated with GM-CSFsecreting tumor cells (83).”
• Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 (2013, background): “…shown to be a marker of a favorable immunological response to immunotherapy in murine tumor models (Quezada et al., 2006; Curran et al., 2010) and has been associated with improved survival (Bui et al., 2006; Sato et al., 2005) and increased tumor necrosis (Hodi et al., 2008) in clinical studies.”
• Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies (2009, background): “Thus, blockade has potentially affected both populations and assigning relative contributions to experimental Furthermore, clinical trials with human anti–human CTLA-4 (aHuCTLA-4) mAbs show promising early results in the treatment of late-stage metastatic melanoma (Hodi et al., 2003; Phan et al., 20”
• Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients (2008, background): “Consistent with this idea, we previously demonstrated that a single infusion of anti-CTLA-4 antibody (3 mg/kg of MDX-010, Ipilumimab) triggered striking tumor necrosis without severe toxicity in five of five metastatic melanoma or ovarian carcinoma patients who were previously immunized with GVAX (2”